Dr. Lalani on Neutrophil-Lymphocyte Ratio in RCC

Video

Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses neutrophil-lymphocyte ratio in renal cell carcinoma.

Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses neutrophil-lymphocyte ratio in renal cell carcinoma (RCC).

The ratio of neutrophil to lymphocytes was compared in a study of patients with RCC treated with immunotherapy.

Neutrophils reflect the inflammatory cascade in patients with cancer, says Lalani, and lymphocytes are an important antitumor agent.

Related Videos
Jose A. Karam, MD, FACS
Amer Zeidan, MBBS
Eric Jonasch, MD
Ulka Nitin Vaishampayan, MBBS
Erica L. Mayer, MD, MPH
Christopher M. Gallagher, MD
Lyudmila A. Bazhenova, MD
Benjamin Philip Levy, MD
John N. Allan, MD
Nicole Lamanna, MD
Related Content
Roberto Iacovelli, MD, PhD

Study Shows Feasibility of IO Maintenance After IO/VEGF TKI Response in Previously Untreated Metastatic ccRCC

November 17th 2023
Article
Neal Shore, MD, FACS

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023
Podcast
Michael E. Hurwitz, MD, PhD

Research Aims to Make Inroads With CAR T-Cell Therapy in Advanced RCC

November 11th 2023
Article
Kyle A. Blum, MD, MS

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022
Podcast
Vivek Narayan, MD, MSCE

Cancer Immunity Cycle Could Inform Development of Novel Immune Therapies in RCC

November 11th 2023
Article
Alan Tan, MD

Treatment Decisions in RCC Could Be Aided by ctDNA

November 11th 2023
Article